MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Patrick DeMartino, MD; Bridget Bradley, PharmD; Douglas Carr, MD; Tim Langford, PharmD; Eriko Onishi, MD; Eddie Saito, PharmD; Ad-Hoc: Erika Finanger, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Kendal Pucik, PharmD Candidate 2024; Brandon Wells; Trevor Douglass, DC; Jennifer Bowen; Kyle Hamilton

Audience: Craig Sexton*, GSK; Nirmal Ghuman*, J&J; Tao Wang*, Climate Works; Brian Denger*, Parent Project Muscular Dystrophy; Adam Gold*, NS Pharma; Armen Khachatourian*, Sarepta; Mark Kantor, AllCare Health; Robin Wells, NS Pharma; Suzanne Morgan, NS Pharma; Melissa Abbott, Eisai; Lori McDermott, Viking HCS; Mike Donabedian, Sarepta; Jim Cromwell, Sarepta; Shirley Kim, Sarepta; Leslie Zanetti, Sarepta; Mindy Cameron; Chris VanWynen, Sarepta; Leif Bruce, Novo Nordisk; Gary Parenteau, Dexcom; Brielle Dozier, Artia Solutions; Tracy Copeland, Sarepta; Brandie Ferger, Advanced Health; Yesina Camacho, PharmD Candidate w/ Umpqua Health; Saghi Maleki, Takeda; Lisa Pulver, J&J; Chris Ferrin, IHN; Leanne Yantis, AllCare; Robert Pearce, Karuna; Uche Mordi, Karuna; Cheryl Bondy, Sobi; Emily Cooper; Alexandria Jarvais, Sobi; Matt Worthy, OHSU; Tiina Andrews, UHA; Mark England, Mercer; Daria Meleshkina, Moda/EOCCO; Samyukta Vendrachi; Long Nguyen; Philip Santa Maria; Bryan Armstrong, CareOregon; Melissa Bailey Hall; Susan Lakey Kevo; Melissa Snider, Gilead; Michele Sabados, Alkermes; Paul Thompson, Alkermes; Shauna Wick, Trillium; Jeff White, Sumitomo; Amy Alkins, Little Hercules Foundation; Richie Kahn, Canary Advisors; Kate Ogden

(*) Provided verbal testimony
I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:05 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Election of Chair and Vice Chair
   Dr. Ramirez volunteered to serve as Chair and Dr. DeMartino as Vice-Chair
   ACTION: Motion to approve, 2nd, all in favor
D. Approval of Agenda and December 2023 Minutes presented by Mr. Citron
   ACTION: Motion to approve, 2nd, all in favor with one abstention
E. Department Update provided by Andrew Gibler, PharmD
F. Legislative Update provided by Trevor Douglass, DC, MPH

II. CONSENT AGENDA TOPICS

A. Preferred Drug List (PDL): Insulin Literature Scan - Deferred to April P&T Meeting
B. P&T Evidence Methods
C. P&T Operating Procedures
D. Oncology Prior Authorization (PA) Updates
   Recommendation:
   - Add: Akeega™ (abiraterone acetate/niraparib tosylate); Truqap™ (capivasertib); Xalkori® (crizotinib); Fruzaql™ (fruquintinib); Hepzato Kit™ (Melphalan HCl/hepatic delivery kit (HDS)); Ogsiveo™ (niragacestat hydrobromide); Augtyro™ (repotrectinib); and Loqtorzi™ (toripalimab-tpzi) to Table 1 in the Oncology Agents PA criteria
E. Orphan Drug Policy Updates
   Recommendation:
   - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Reblozy™ (luspatercept-amt); and Bylvay™ (odevixibat) based on FDA-approved label
   ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. Quarterly Utilization Report: Roger Citron, RPh
B. ProDUR Report: Lan Starkweather, PharmD
C. RetroDUR Report: Dave Engen, PharmD
D. Oregon State Drug Review: Kathy Sentena, PharmD
   1. An Update in Weight Loss Therapies-Including FDA Approved GLP-1 Receptor Agonists
IV. DUR OLD BUSINESS

A. Spravato® (esketamine) PA Update: Sarah Servid, PharmD

Recommendation:
- Update the safety edit for esketamine to include outpatient initiation for people with suicidal ideation who have optimized first-line alternative treatments for depression

Public Comment: Nirmal Ghuman, J&J

ACTION: The Committee recommended ensuring the approved doses match the FDA approved labeling for each indication

Motion to approve, 2nd, all in favor

V. DUR NEW BUSINESS

A. Antipsychotics in Children Policy Evaluation: Sarah Servid, PharmD

Recommendation:
- Update the Antipsychotics in Children safety edit to include assessment of rapid weight gain for members without glucose monitoring, consider allowing longer initial therapy before PA is required, and apply the policy to members who are three to six years of age

ACTION: The Committee recommended allowing up to 60 days initial therapy before PA is required and to explore options to notify providers about the policy before members have a denied claim

Motion to approve, 2nd, all in favor

B. Melatonin Policy Evaluation:
Kendal Pucik, PharmD Candidate 2024 and Megan Herink, PharmD

Recommendations:
- No policy changes recommended based on the policy evaluation

ACTION: Motion to approve, 2nd, all in favor

VI. PREFERRED DRUG LIST (PDL) NEW BUSINESS

A. Lantidra™ (donislecel) New Drug Evaluation: Kathy Sentena, PharmD

Recommendations:
- Implement the proposed PA for donislecel to ensure that it is used in patients in which the benefits outweigh the risks of transplant

ACTION: Motion to approve, 2nd, all in favor
B. **Maintenance Inhalers for Asthma/COPD**: Deanna Moretz, PharmD  
**Recommendations:**  
- Designate at least one long-acting muscarinic antagonist-long-acting beta agonist (LAMA-LABA) combination agent preferred on the PMPDP PDL changes recommended based on the review of recently published evidence  
- Remove PA requirements for preferred LAMA-LABA and preferred long-acting muscarinic antagonist-long-acting beta agonist-inhaled corticosteroid (LAMA-LABA-ICS) combination products  
- Maintain Airsupra™ (albuterol-budesonide) and Symbicort® Aerosphere™ (budesonide 160 mcg-formoterol 4.8 mcg) as non-preferred inhalers on the PMPDP  
- Evaluate costs in executive session  
**Public Comment:** Craig Sexton, GSK  
**ACTION:** Motion to approve, 2nd, all in favor

C. **Duchenne Muscular Dystrophy DERP Report and NDE**: Sarah Servid, PharmD  
**Recommendations:**  
- Implement the proposed PA criteria for delandistrogene moxeparvovec (Elevidys™) to limit use to the FDA-approved indication  
- Based on the review of recently published evidence no PDL changes to the preferred corticosteroids were recommended  
- Update the DMD PA criteria to apply to all non-preferred corticosteroids for DMD  
- Evaluate costs in executive session  
**Public Comment:** Tao Wang, parent; Brian Denger, Parent Project Muscular Dystrophy; Adam Gold, NS Pharma; Armen Khachatourian, Sarepta  
**ACTION:** The Committee modified the proposed PA criteria to require prescribing by a neuromuscular specialist and to require documentation of informed consent for members with deletions of exons 1-17 or 59-71  
**Motion to approve, 2nd, all in favor with one abstention**

D. **Antivirals for SARS-CoV2 Class Review**: Deferred to April P&T Meeting

---

**VII. EXECUTIVE SESSION**

**Members Present:** Stacy Ramirez, PharmD; Patrick DeMartino, MD; Bridget Bradley, PharmD; Douglas Carr, MD; Eriko Onishi, MD; Eddie Saito, PharmD; **Ad-Hoc:** Erika Finanger, MD
Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Kendal Pucik, PharmD Candidate 2024; Brandon Wells; Kyle Hamilton

VIII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Maintenance Inhalers for Asthma/COPD
   Recommendation: Make Arnuity™ Ellipta® (fluticasone furoate) preferred
   ACTION: Motion to approve, 2nd, all in favor

B. Duchenne Muscular Dystrophy (DMD)
   Recommendations: Designate all targeted DMD therapies as non-preferred and make Emflaza® (deflazacort) and Agamree® (vamorolone) non-preferred
   ACTION: Motion to approve, 2nd, all in favor with one abstention

IX. ADJOURN